Emergent BioSolutions (EBS) Free Cash Flow Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn | -144.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -144.59% |
| Dec 31, 2025 | 195.47% |
| Sep 30, 2025 | -98.38% |
| Jun 30, 2025 | 192.37% |
| Mar 31, 2025 | 77.54% |
| Dec 31, 2024 | -692.23% |
| Sep 30, 2024 | 88.65% |
| Jun 30, 2024 | 126.38% |
| Mar 31, 2024 | 65.64% |
| Dec 31, 2023 | -105.87% |
| Sep 30, 2023 | 176.94% |
| Jun 30, 2023 | -181.34% |
| Mar 31, 2023 | -175.97% |
| Dec 31, 2022 | -43.01% |
| Sep 30, 2022 | -310.54% |
| Jun 30, 2022 | -65.05% |
| Mar 31, 2022 | -153.65% |
| Dec 31, 2021 | 20.49% |
| Sep 30, 2021 | -68.73% |
| Jun 30, 2021 | -131.14% |